187 related articles for article (PubMed ID: 10888237)
1. The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.
Liang B; McMaster JC; Kroeger EA; Hatch GM; Mymin D; Dembinski T; Arthur G; Shen G; Man RY; Choy PC
Mol Cell Biochem; 2000 Apr; 207(1-2):123-9. PubMed ID: 10888237
[TBL] [Abstract][Full Text] [Related]
2. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation.
Chen L; Liang B; Froese DE; Liu S; Wong JT; Tran K; Hatch GM; Mymin D; Kroeger EA; Man RY; Choy PC
J Lipid Res; 1997 Mar; 38(3):546-53. PubMed ID: 9101435
[TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients.
Zhu Q; McMaster J; Mymin D; Dembinski T; Hatch G; Choy PC; Kroeger EA
Mol Cell Biochem; 2000 Apr; 207(1-2):9-17. PubMed ID: 10888221
[TBL] [Abstract][Full Text] [Related]
4. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
5. Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism.
Chan H; Lougheed M; Laher I; Steinbrecher UP
J Cardiovasc Pharmacol; 2003 Jun; 41(6):856-65. PubMed ID: 12775962
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate attenuates nicotine-induced vascular endothelial dysfunction in the rat.
Chakkarwar VA
Vascul Pharmacol; 2011; 55(5-6):163-8. PubMed ID: 21864717
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
8. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
[TBL] [Abstract][Full Text] [Related]
9. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation.
Liu SY; Lu X; Choy S; Dembinski TC; Hatch GM; Mymin D; Shen X; Angel A; Choy PC; Man RY
Cardiovasc Res; 1994 Oct; 28(10):1476-81. PubMed ID: 8001034
[TBL] [Abstract][Full Text] [Related]
10. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
11. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation.
Deckert V; Perségol L; Viens L; Lizard G; Athias A; Lallemant C; Gambert P; Lagrost L
Circulation; 1997 Feb; 95(3):723-31. PubMed ID: 9024163
[TBL] [Abstract][Full Text] [Related]
13. High density lipoprotein and low density lipoprotein attenuate the inhibitory effects of oxidized low density lipoprotein on endothelium-dependent arterial relaxation.
Matsuda Y
Kobe J Med Sci; 1993 Feb; 39(1):1-14. PubMed ID: 8366661
[TBL] [Abstract][Full Text] [Related]
14. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation.
Matsuda Y; Hirata K; Inoue N; Suematsu M; Kawashima S; Akita H; Yokoyama M
Circ Res; 1993 May; 72(5):1103-9. PubMed ID: 8477522
[TBL] [Abstract][Full Text] [Related]
15. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein.
Yokoyama M; Hirata K; Miyake R; Akita H; Ishikawa Y; Fukuzaki H
Biochem Biophys Res Commun; 1990 Apr; 168(1):301-8. PubMed ID: 2328007
[TBL] [Abstract][Full Text] [Related]
18. Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: role of enhanced oxidative stress.
Galle J; Schneider R; Winner B; Lehmann-Bodem C; Schinzel R; Münch G; Conzelmann E; Wanner C
Atherosclerosis; 1998 May; 138(1):65-77. PubMed ID: 9678772
[TBL] [Abstract][Full Text] [Related]
19. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats.
Kobayashi T; Matsumoto T; Kamata K
Br J Pharmacol; 2000 Sep; 131(2):231-8. PubMed ID: 10991915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
